ReviewExpert review of vaccines2017
Vaccine development for syphilis.
Review in Expert review of vaccines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Neurosyphilis-Induced Psychosis in Europe: A Systematic Review of Case Reports.Pathogens (Basel, Switzerland) · 2024Pooled it
- An mRNA-LNP vaccine expressing TP0435 provides protective immunity in rabbits againstEmerging microbes & infections · 2026Article
- Looking down the road: development and distribution of a future syphilis vaccine.Sexually transmitted diseases · 2026Article
- Article
- Article
- Dual Immunization with Lipoprotein Tp0663 and Flagellin FlaB3 Offers Augmented Protection againstACS omega · 2025Article
- Syphilis vaccine development: Aligning vaccine design with manufacturing requirements.Human vaccines & immunotherapeutics · 2024Article
- Immunity to Sexually Transmitted Bacterial Infections of the Female Genital Tract: Toward Effective Vaccines.Vaccines · 2024Review
- Cytokine profiles in an extremely preterm infant with congenital syphilis.Fukushima journal of medical science · 2023Article
- Prevention strategies for sexually transmitted infections, HIV, and viral hepatitis in Europe.The Lancet regional health. Europe · 2023Review
- Insights into the protective immune response by immunization with full-length recombinant TprK protein: cellular and humoral responses.NPJ vaccines · 2023Article
- Advancements in the development of nucleic acid vaccines for syphilis prevention and control.Human vaccines & immunotherapeutics · 2023Review
- Neurosyphilis: insights into its pathogenesis, susceptibility, diagnosis, treatment, and prevention.Frontiers in neurology · 2023Review
- Immunization with Tp0954, an adhesin ofFrontiers in immunology · 2023Article
- Article
- Assessment of recombinant antigens Tp0100 and Tp1016 of Treponema pallidum for serological diagnosis of syphilis.Journal of clinical laboratory analysis · 2022Article
- Article
- In Silico Designed Multi-Epitope Immunogen "Tpme-VAC/LGCM-2022" May Induce Both Cellular and Humoral Immunity againstVaccines · 2022Article
- Strategies for successful designing of immunocontraceptive vaccines and recent updates in vaccine development against sexually transmitted infections - A review.Saudi journal of biological sciences · 2022Review
- B-Cell Epitope Mapping of TprC and TprD Variants ofFrontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionSyphilis, caused by the spirochete Treponema pallidum subspecies pallidum, continues to be a globally prevalent disease despite remaining susceptible to penicillin treatment. Syphilis vaccine development is a viable preventative approach that will serve to complement public health-oriented syphilis prevention, screening and treatment initiatives to deliver a two-pronged approach to stemming disease spread worldwide. Areas covered: This article provides an overview of the need for development of a syphilis vaccine, summarizes significant information that has been garnered from prior syphilis vaccine studies, discusses the critical aspects of infection that would have to be targeted by a syphilis vaccine, and presents the current understanding within the field of the correlates of protection needed to be achieved through vaccination. Expert commentary: Syphilis vaccine development should be considered a priority by industry, regulatory and funding agencies, and should be appropriately promoted and supported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.